Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation

Jong Cheol Jeong, Enkthuya Jambaldorj, Hyuk Yong Kwon, Myung-Gyu Kim, Hye Jin Im, Hee Jung Jeon, Ji Won In, Miyeun Han, Tai Yeon Koo, Junho Chung, Eun Young Song, Curie Ahn, Jaeseok Yang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Combination therapy of intravenous immunoglobulin (IVIG) and rituximab showed a good transplant rate in highly sensitized wait-listed patients for deceased donor kidney transplantation (DDKT), but carried the risk of antibody-mediated rejection. The authors investigated the impact of a new combination therapy of bortezomib, IVIG, and rituximab on transplantation rate. This study was a prospective, open-labeled clinical trial. The desensitization regimen consisted of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m2), and 4 doses of bortezomib (1.3 mg/m2). The transplant rate was analyzed. Anti-Human leukocyte antigen (HLA) DRB antibodies were determined by a Luminex solid-phase bead assay at baseline and after 2, 3, and 6 months in the desensitized patients. There were 19 highly sensitized patients who received desensitization and 17 patients in the control group. Baseline values of class I and II panel reactive antibody (%, peak mean fluorescence intensity) were 83±16.0 (14952±5820) and 63±36.0 (10321±7421), respectively. Deceased donor kidney transplantation was successfully performed in 8 patients (42.1%) in the desensitization group versus 4 (23.5%) in the control group. Multivariate time-varying covariate Cox regression analysis showed that desensitization increased the probability of DDKT (hazard ratio, 46.895; 95% confidence interval, 3.468-634.132; P1/40.004). Desensitization decreased mean fluorescence intensity values of class I panel reactive antibody by 15.5% (20.8%) at 2 months. In addition, a liberal mismatch strategy in post hoc analysis increased the benefit of desensitization in donor-specific antibody reduction. Desensitization was well tolerated, and acute rejection occurred only in the control group. In conclusion, a desensitization protocol using bortezomib, highdose IVIG, and rituximab increased the DDKT rate in highly sensitized, wait-listed patients.

Original languageEnglish
Article numbere2635
JournalMedicine (United States)
Volume95
Issue number5
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Kidney Transplantation
Immunoglobulins
Intravenous Immunoglobulins
Tissue Donors
Antibodies
Control Groups
Fluorescence
Dichlororibofuranosylbenzimidazole
Transplants
HLA Antigens
Bortezomib
Transplantation
Regression Analysis
Clinical Trials
Confidence Intervals
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation. / Jeong, Jong Cheol; Jambaldorj, Enkthuya; Kwon, Hyuk Yong; Kim, Myung-Gyu; Im, Hye Jin; Jeon, Hee Jung; In, Ji Won; Han, Miyeun; Koo, Tai Yeon; Chung, Junho; Song, Eun Young; Ahn, Curie; Yang, Jaeseok.

In: Medicine (United States), Vol. 95, No. 5, e2635, 01.01.2016.

Research output: Contribution to journalArticle

Jeong, JC, Jambaldorj, E, Kwon, HY, Kim, M-G, Im, HJ, Jeon, HJ, In, JW, Han, M, Koo, TY, Chung, J, Song, EY, Ahn, C & Yang, J 2016, 'Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation', Medicine (United States), vol. 95, no. 5, e2635. https://doi.org/10.1097/MD.0000000000002635
Jeong, Jong Cheol ; Jambaldorj, Enkthuya ; Kwon, Hyuk Yong ; Kim, Myung-Gyu ; Im, Hye Jin ; Jeon, Hee Jung ; In, Ji Won ; Han, Miyeun ; Koo, Tai Yeon ; Chung, Junho ; Song, Eun Young ; Ahn, Curie ; Yang, Jaeseok. / Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation. In: Medicine (United States). 2016 ; Vol. 95, No. 5.
@article{af6ee531f88446ed8ed00d25930af652,
title = "Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation",
abstract = "Combination therapy of intravenous immunoglobulin (IVIG) and rituximab showed a good transplant rate in highly sensitized wait-listed patients for deceased donor kidney transplantation (DDKT), but carried the risk of antibody-mediated rejection. The authors investigated the impact of a new combination therapy of bortezomib, IVIG, and rituximab on transplantation rate. This study was a prospective, open-labeled clinical trial. The desensitization regimen consisted of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m2), and 4 doses of bortezomib (1.3 mg/m2). The transplant rate was analyzed. Anti-Human leukocyte antigen (HLA) DRB antibodies were determined by a Luminex solid-phase bead assay at baseline and after 2, 3, and 6 months in the desensitized patients. There were 19 highly sensitized patients who received desensitization and 17 patients in the control group. Baseline values of class I and II panel reactive antibody ({\%}, peak mean fluorescence intensity) were 83±16.0 (14952±5820) and 63±36.0 (10321±7421), respectively. Deceased donor kidney transplantation was successfully performed in 8 patients (42.1{\%}) in the desensitization group versus 4 (23.5{\%}) in the control group. Multivariate time-varying covariate Cox regression analysis showed that desensitization increased the probability of DDKT (hazard ratio, 46.895; 95{\%} confidence interval, 3.468-634.132; P1/40.004). Desensitization decreased mean fluorescence intensity values of class I panel reactive antibody by 15.5{\%} (20.8{\%}) at 2 months. In addition, a liberal mismatch strategy in post hoc analysis increased the benefit of desensitization in donor-specific antibody reduction. Desensitization was well tolerated, and acute rejection occurred only in the control group. In conclusion, a desensitization protocol using bortezomib, highdose IVIG, and rituximab increased the DDKT rate in highly sensitized, wait-listed patients.",
author = "Jeong, {Jong Cheol} and Enkthuya Jambaldorj and Kwon, {Hyuk Yong} and Myung-Gyu Kim and Im, {Hye Jin} and Jeon, {Hee Jung} and In, {Ji Won} and Miyeun Han and Koo, {Tai Yeon} and Junho Chung and Song, {Eun Young} and Curie Ahn and Jaeseok Yang",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MD.0000000000002635",
language = "English",
volume = "95",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation

AU - Jeong, Jong Cheol

AU - Jambaldorj, Enkthuya

AU - Kwon, Hyuk Yong

AU - Kim, Myung-Gyu

AU - Im, Hye Jin

AU - Jeon, Hee Jung

AU - In, Ji Won

AU - Han, Miyeun

AU - Koo, Tai Yeon

AU - Chung, Junho

AU - Song, Eun Young

AU - Ahn, Curie

AU - Yang, Jaeseok

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Combination therapy of intravenous immunoglobulin (IVIG) and rituximab showed a good transplant rate in highly sensitized wait-listed patients for deceased donor kidney transplantation (DDKT), but carried the risk of antibody-mediated rejection. The authors investigated the impact of a new combination therapy of bortezomib, IVIG, and rituximab on transplantation rate. This study was a prospective, open-labeled clinical trial. The desensitization regimen consisted of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m2), and 4 doses of bortezomib (1.3 mg/m2). The transplant rate was analyzed. Anti-Human leukocyte antigen (HLA) DRB antibodies were determined by a Luminex solid-phase bead assay at baseline and after 2, 3, and 6 months in the desensitized patients. There were 19 highly sensitized patients who received desensitization and 17 patients in the control group. Baseline values of class I and II panel reactive antibody (%, peak mean fluorescence intensity) were 83±16.0 (14952±5820) and 63±36.0 (10321±7421), respectively. Deceased donor kidney transplantation was successfully performed in 8 patients (42.1%) in the desensitization group versus 4 (23.5%) in the control group. Multivariate time-varying covariate Cox regression analysis showed that desensitization increased the probability of DDKT (hazard ratio, 46.895; 95% confidence interval, 3.468-634.132; P1/40.004). Desensitization decreased mean fluorescence intensity values of class I panel reactive antibody by 15.5% (20.8%) at 2 months. In addition, a liberal mismatch strategy in post hoc analysis increased the benefit of desensitization in donor-specific antibody reduction. Desensitization was well tolerated, and acute rejection occurred only in the control group. In conclusion, a desensitization protocol using bortezomib, highdose IVIG, and rituximab increased the DDKT rate in highly sensitized, wait-listed patients.

AB - Combination therapy of intravenous immunoglobulin (IVIG) and rituximab showed a good transplant rate in highly sensitized wait-listed patients for deceased donor kidney transplantation (DDKT), but carried the risk of antibody-mediated rejection. The authors investigated the impact of a new combination therapy of bortezomib, IVIG, and rituximab on transplantation rate. This study was a prospective, open-labeled clinical trial. The desensitization regimen consisted of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m2), and 4 doses of bortezomib (1.3 mg/m2). The transplant rate was analyzed. Anti-Human leukocyte antigen (HLA) DRB antibodies were determined by a Luminex solid-phase bead assay at baseline and after 2, 3, and 6 months in the desensitized patients. There were 19 highly sensitized patients who received desensitization and 17 patients in the control group. Baseline values of class I and II panel reactive antibody (%, peak mean fluorescence intensity) were 83±16.0 (14952±5820) and 63±36.0 (10321±7421), respectively. Deceased donor kidney transplantation was successfully performed in 8 patients (42.1%) in the desensitization group versus 4 (23.5%) in the control group. Multivariate time-varying covariate Cox regression analysis showed that desensitization increased the probability of DDKT (hazard ratio, 46.895; 95% confidence interval, 3.468-634.132; P1/40.004). Desensitization decreased mean fluorescence intensity values of class I panel reactive antibody by 15.5% (20.8%) at 2 months. In addition, a liberal mismatch strategy in post hoc analysis increased the benefit of desensitization in donor-specific antibody reduction. Desensitization was well tolerated, and acute rejection occurred only in the control group. In conclusion, a desensitization protocol using bortezomib, highdose IVIG, and rituximab increased the DDKT rate in highly sensitized, wait-listed patients.

UR - http://www.scopus.com/inward/record.url?scp=84958811356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958811356&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000002635

DO - 10.1097/MD.0000000000002635

M3 - Article

VL - 95

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 5

M1 - e2635

ER -